title: Imaging beyond RECIST: CT and MRI in molecular therapies.
abstract: Until recently, almost all systemic antineoplastic therapies in cancer patients aimed at destruction of tumor cells, i.e. they were cytotoxic. The effect of therapy was assessed by measuring the tumor size with a decrease in size suggesting response to therapy and an increase suggesting progression. Modern molecular therapies, however, are mostly not cytotoxic but aim to reduce tumor perfusion or metabolism by blocking specific cell functions without causing cell death. Assessment of tumor size alone may, therefore, not be appropriate in this setting and can even lead to false conclusions. This presentation gives examples of changes at computed tomography (CT) and magnetic resonance imaging (MRI) of tumors undergoing therapy with molecular therapies, highlights potential pitfalls und suggests criteria for response assessment. The presentation focuses on CT and MRI of chest and abdominal tumors and specifically excludes positron emission tomography/CT and brain tumors.
authors.affiliation: Department of Diagnostic and Interventional Radiology, Marien Hospital Düsseldorf, Academic Teaching Hospital, Germany. s.diederich@marien-hospital.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Diederich
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents